EmerGen

EmerGen is a clinical-stage biotechnology company specializing in the development of next-generation T-cell epitope-based vaccines for infectious diseases and oncology. Utilizing its proprietary T-cell epitope identification platform, the company designs vaccines that trigger robust cellular immune responses, aiming to provide broader and more durable protection than traditional antibody-focused vaccines. Its lead candidate, EG-001, is a T-cell vaccine for COVID-19, with other programs targeting Hepatitis B (HBV), Human Papillomavirus (HPV), and various cancers. Headquartered in Beijing with a research presence in Gaithersburg, Maryland, EmerGen is positioned at the forefront of cellular immunity research.